Disclosed is a recombinant human insulin or analog conjugate thereof. Said conjugate is formed by connecting the ε-amino group of lysine 29 of the B chain to activated polyethylene glycol by means of an amide bond. Further disclosed is a method of preparing said conjugate, a pharmaceutical compound, and a use for said conjugate in preparing medication for treating Type 1 and Type 2 diabetes.